Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of TCR-NK Therapy ZI-MA4-1 Targeting Solid Tumours
“We are thrilled to have successfully locked down our TCR-NK cell therapy manufacturing process,” said Namir Hassan, CEO of Zelluna. “This pivotal achievement not only demonstrates our capability to produce high-quality, scalable TCR-NK cell therapies, but also underscores our commitment to advancing next-generation immunotherapies that could transform the treatment of solid tumours and improve patient outcomes. This accomplishment is a testament to the exceptional talent and relentless drive of our team and partners.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.